PMID- 31171461
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20221207
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
VI  - 14
IP  - 1
DP  - 2020 Feb
TI  - Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What 
      effect should we expect in routine clinical practice?
PG  - 68-74
LID - S1751-9918(19)30003-8 [pii]
LID - 10.1016/j.pcd.2019.05.006 [doi]
AB  - AIM: Liraglutide and lixisenatide improved glycemic control, weight and 
      cardiovascular risk factors (CVRF) in type 2 diabetes mellitus (T2DM) patients. 
      Our objective was to analyze clinical efficacy and safety differences in routine 
      clinical practice. METHODS: A 24-week prospective observational study to compare 
      the effect of liraglutide versus lixisenatide in obese T2DM patients in routine 
      clinical practice. The main objective was to analyze between-group glycosylated 
      hemoglobin (HbA(1c)) differences at the end of the study. Secondary objectives 
      included differences in body weight, other CVRF, changes in medication, side 
      effects, satisfaction and safety. RESULTS: A total of 100 patients (50 
      liraglutide, 50 lixisenatide) were included. Both groups experienced a decrease 
      in HbA(1c) values (liraglutide, -1.4%, CI 95% -2, -0.8, P < 0.001 vs. 
      lixisenatide, -0.8%, 95% CI -1.2, -0.5, P < 0.001). No differences were found in 
      final HbA(1c) values between both groups (liraglutide 7.3 +/- 0.9% vs. lixisenatide 
      7.2 +/- 1.5%, P = 0.7). We did not detect between groups differences in 
      anthropometric variables or CVRF at the study end. A lower proportion of patients 
      received treatment with a maximum dose of liraglutide compared with lixisenatide 
      (27% vs. 95%, P < 0.001). In contrast, a greater percentage of patients in the 
      lixisenatide group than in liraglutide group (29% vs. 9%, P = 0.026) intensified 
      treatment by the addition of sodium-glucose transporter type 2 inhibitors. 
      Adverse events were less frequently reported in liraglutide treated patients 
      compared with lixisentatide (80% vs. 96%, P = 0.014). No serious adverse events 
      were detected. CONCLUSIONS: These results confirm the efficacy and safety of 
      liraglutide and lixisenatide in routine clinical practice. Moreover, a different 
      therapeutic effect between liraglutide and lixisenatide was detected.
CI  - Copyright (c) 2019 Primary Care Diabetes Europe. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Moreno-Fernandez, Jesus
AU  - Moreno-Fernandez J
AD  - Endocrinology and Nutrition Department, Ciudad Real General University Hospital, 
      C/Obispo Rafael Torija, s/n. Ciudad Real, 13005, Spain. Electronic address: 
      jmorenof@sescam.jccm.es.
FAU - Garcia-Seco, Jose Alberto
AU  - Garcia-Seco JA
AD  - Endocrinology and Nutrition Department, Ciudad Real General University Hospital, 
      C/Obispo Rafael Torija, s/n. Ciudad Real, 13005, Spain.
FAU - Seco Segura, Angela Maria
AU  - Seco Segura AM
AD  - Endocrinology and Nutrition Department, Ciudad Real General University Hospital, 
      C/Obispo Rafael Torija, s/n. Ciudad Real, 13005, Spain.
FAU - Garcia-Seco, Fernando
AU  - Garcia-Seco F
AD  - Cordoba University, Avd. Medina Azahara. 5, Cordoba, 14071 Spain.
FAU - Rozas Moreno, Pedro Jesus
AU  - Rozas Moreno PJ
AD  - Endocrinology and Nutrition Department, Ciudad Real General University Hospital, 
      C/Obispo Rafael Torija, s/n. Ciudad Real, 13005, Spain.
FAU - Aguirre Sanchez-Covisa, Miguel
AU  - Aguirre Sanchez-Covisa M
AD  - Endocrinology and Nutrition Department, Ciudad Real General University Hospital, 
      C/Obispo Rafael Torija, s/n. Ciudad Real, 13005, Spain.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20190604
PL  - England
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Peptides)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 74O62BB01U (lixisenatide)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy
MH  - Female
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Liraglutide/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Obesity/diagnosis/*drug therapy/physiopathology
MH  - Peptides/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - Spain
MH  - Time Factors
MH  - Treatment Outcome
MH  - Weight Loss/*drug effects
OTO - NOTNLM
OT  - GLP-1 receptor agonists
OT  - Liraglutide
OT  - Lixisenatide
OT  - Obesity
OT  - Routine clinical practice
OT  - Type 2 diabetes mellitus
EDAT- 2019/06/07 06:00
MHDA- 2021/01/27 06:00
CRDT- 2019/06/08 06:00
PHST- 2019/01/02 00:00 [received]
PHST- 2019/04/29 00:00 [revised]
PHST- 2019/05/12 00:00 [accepted]
PHST- 2019/06/07 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
PHST- 2019/06/08 06:00 [entrez]
AID - S1751-9918(19)30003-8 [pii]
AID - 10.1016/j.pcd.2019.05.006 [doi]
PST - ppublish
SO  - Prim Care Diabetes. 2020 Feb;14(1):68-74. doi: 10.1016/j.pcd.2019.05.006. Epub 
      2019 Jun 4.